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Hereditary spastic paraplegias (HSPs) form a heterogeneous group of neurological disorders. Awhole-genome linkagemapping effort was
made with three HSP-affected families from Spain, Portugal, and Tunisia and it allowed us to reduce the SPG26 locus interval from 34 to 9
Mb. Subsequently, a targeted capture was made to sequence the entire exome of affected individuals from these three families, as well as
from two additional autosomal-recessive HSP-affected families of German and Brazilian origins. Five homozygous truncating (n¼ 3) and
missense (n ¼ 2) mutations were identified in B4GALNT1. After this finding, we analyzed the entire coding region of this gene in 65
additional cases, and three mutations were identified in two subjects. All mutated cases presented an early-onset spastic paraplegia,
with frequent intellectual disability, cerebellar ataxia, and peripheral neuropathy as well as cortical atrophy and white matter hyperin-
tensities on brain imaging. B4GALNT1 encodes b-1,4-N-acetyl-galactosaminyl transferase 1 (B4GALNT1), involved in ganglioside
biosynthesis. These findings confirm the increasing interest of lipid metabolism in HSPs. Interestingly, although the catabolism of gan-
gliosides is implicated in a variety of neurological diseases, SPG26 is only the second human disease involving defects of their biosyn-
thesis.Hereditary spastic paraplegias (HSPs) constitute a clinically
and genetically heterogeneous group of neurodegenerative
conditions. They are characterized by a slowly progressive
spasticity of the lower extremities resulting from the
axonal degeneration and/or dysfunction observed in
long axons of the corticospinal tracts.1,2 HSPs are classified
according to the following criteria: (1) absence (uncompli-
cated or pure HSP) or presence (complicated or complex
HSP) of additional neurological signs and symptoms,
including intellectual disability, cerebellar ataxia, periph-
eral neuropathy, retinopathy, cataract, epilepsy, and ich-
thyosis; and (2) mode of inheritance in the case of familial
forms, which can be autosomal-dominant, autosomal-
recessive (AR), mitochondrial, or X-linked.3 To date, more
than 55 HSP loci (denoted SPG) have been mapped.
Among them, mutations have been found in ~33 genes;
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In 2005, Wilkinson et al. mapped the SPG26 locus (MIM
609195) to a 22.8 cM region flanked by markers
D12S59 and D12S1676 (34.2 Mb) on chromosome
12p11.1–12q14 in a Kuwaiti family with AR complicated
HSP.9 In the present study, we linked additional HSP fam-
ilies to the SPG26 locus, refined the locus region, identified
the segregating mutations in seven of these families, and
described the associated phenotype.
We selected three families in which diagnosis of AR HSP
was established according to Harding’s criteria and careful
exclusion of alternative disorders.10 Blood samples and
clinical assessments were performed after informed con-
sent and after local ethics approvals. The disease was not
caused by mutations in any of the frequently involved
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Figure 1. SPG26 Pedigrees and Segregation of the Mutations Detected in B4GALNT1
Square symbols indicate males and circles indicate females. Filled symbols indicate affected individuals. The numbers are an internal
reference for each sampled individual. Stars indicate sampled subjects. Abbreviations are as follows: M, mutation; þ, wild-type.(n ¼ 4) and unaffected (n ¼ 5) members of a Tunisian fam-
ily (TUN34) were subjected to a genome-wide linkage map-
ping that used 6,090 SNP markers (LINKAGE_24 Illumina)
and an additional 30 microsatellite markers, as previously
described.11 All four affected individuals shared a single re-
gion of homozygosity of 22.5 cM (24 Mb) on chromosome
12 flanked by markers D12S1632 (56,415,415 bp) and
D12S2074 (80,431,457 bp) (Figure S1 available online).
Pairwise LOD scores reached the significance value of þ3
at 19 consecutive markers with a multipoint LOD score
of þ4.45 (data not shown). In three affected and three un-
affected subjects of a Spanish family (FSP112), the genome-
wide scan was performed with 428 microsatellite markers,
including the ABI Mapping set (Applied Biosystems), as
described.12 In a single homozygous region of 33 cM
(41 Mb), a maximal multipoint LOD score of þ2.53
reached the maximal expected value in this pedigree,
flanked by markers D12S1617 and D12S1686 (Figure S1).
Both homozygous regions in families TUN34 and FSP112
overlapped with the SPG26 candidate interval and allowed
its reduction from 34.2 Mb (27 cM) to 9.3 Mb (6.9 cM) be-
tween D12S1632 and D12S1686 (Figure S1). In a third fam-
ily, of Portuguese origin without known consanguinityThe Am(FSP995), the same strategy was employed using the Illu-
mina SNP panel and identified 10 regions with positive
LOD score values ranging from þ0.2 to þ2.25, including
a large portion of chromosome 12 containing SPG26.
Exome sequencing was performed on affected subjects
of families FSP112, FSP995, and TUN34 as well as in two
additional families, IHG25297 from Brazil and THI26004
from Germany (Figure 1). Coding exons and flanking
intronic sequences were enriched with the SureSelect Hu-
man All Exon 50 Mb kit (Agilent) according to the manu-
facturer’s standard protocol. Enriched samples were pre-
pared for the Hiseq2000 instrument (Illumina) and
paired-end reads of 100 bp length were produced. The Bur-
rows-Wheeler algorithm was applied to align sequence
reads to the UCSC Genome Browser hg19 version of the
human genome and variants were called via the GATK soft-
ware package.13 Data were then imported into dedicated
analysis toolsets, including the online GEnomes Manage-
ment application (GEM.app)14 and Eris (Integragen), for
further analysis. In families TUN34, FSP995, and FSP112,
the variants were filtered according to their quality, func-
tional class (nonsynonymous and/or affecting splicing),
presence in chromosomal regions with putative orerican Journal of Human Genetics 93, 118–123, July 11, 2013 119
Figure 2. Schematic Representation of B4GALNT1/SPG26 and Location of the Mutations
(A) Exon-intron structure of B4GALNT1, with positions of mutations identified in seven SPG26-affected families. Exons are indicated as
black boxes. The region encoding a functional domain is indicated by blue bars.
(B) Phylogenetic conservation of three amino acids mutated in SPG26-affected individuals.
(C) Electropherograms of the mutations identified. Mutation nomenclature is in agreement with ALAMUT 2.2 and Mutalyzer software
with transcript NM_001478.3.nonexcluded linkage, and frequency %1% in publically
available genomic databases. Together, these criteria
helped to reduce the list of variants to two to five variants
per family (Table S1). Based on conservation and variant
class, we restricted this list to single mutations for each
family that were all in the same gene, B4GALNT1 (MIM
601873; RefSeq accession number NM_001478.3):
c.898C>T (p.Arg300Cys), c.358C>T (p.Gln120*), and
c.395delC (p.Pro132Glnfs*7), respectively. In family
IHG25397, filtering of exome variants under a recessive
model identified three candidate variants, one being a
homozygous stop mutation in B4GALNT1 (c.682C>T
[p.Arg228*]). Similarly, a single homozygous variant in
B4GALNT1 remained under the same filters in family
THI26004 (c.1298A>C [p.Asp433Ala]) (Table S1).120 The American Journal of Human Genetics 93, 118–123, July 11, 2We then screened a series of 65 index cases of HSP fam-
ilies compatible with an ARmode of inheritance and found
three other mutations in two simplex cases. One homo-
zygous truncating mutation was identified in a consan-
guineous Algerian subject (FSP1007-8: c.263dupG
[p.Leu89Profs*13]). A French HSP case harbored com-
pound heterozygote changes: one codon deletion affecting
a conserved amino acid and one in-frame duplication of
two codons (FSP852-1: c.1315_1317delTTC [p.Phe439del]
and c.917_922dup [p.Thr307_Val308dup]). For the latter
case, it was not possible to verify whether they segregated
in cis or in trans (Figures 1 and 2).
These mutations all segregated with the disease in their
respective pedigree, when it could be tested (Figure 1),
and they were also absent from the Exome Variant Server013
Figure 3. Simplified Representation of
Ganglioside Metabolism and Their
Related Disorders
Arrows indicate the orientation of the
enzymatic reactions and the correspond-
ing enzymes are indicated in black. Meta-
bolic diseases are indicated in blue at the
corresponding altered reaction. Ganglio-
side formation is performed in the endo-
plasmic reticulum and Golgi by successive
glycosylations. Their degradation takes
place in lysosomes. Abbreviations are as
follows: hex, hexosaminidase; Gb3, globo-
trioaosylceramide; GBA, glucocerebrosi-
dase; GD, disialic ganglioside; GALC, gal-
actosylceramide-beta-galactosidase; GLA,
alpha galactosidase; GLB, beta galac-
tosidase; GM, monosialic ganglioside;
GT, trisialic ganglioside; GT3 synthase,
alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase; MLD, metachromatic
leukodystrophy; Sap, saposin.(EVS; 13,006 chromosomes) and our local databases
(>3,340 chromosomes). The two missense variants and
the codon deletion affected strongly conserved amino
acids (Figure 2) in B4GALNT1 and they were all predicted
to be pathogenic when examined with algorithms de-
signed to assess the impact of genetic variations (Polyphen,
MutationTaster, Sift).
B4GALNT1 encodes b-1,4-N-acetyl-galactosaminyl trans-
ferase 1 (GM2/GD2 synthase; EC 2.4.1.92), an enzyme
involved in the biosynthesis of complex gangliosides (G),
which aremono- (M), di- (D), and tri- (T) sialic acid-contain-
ing glycosphingolipids generated by sequential glycosyla-
tions (Figure 3).15 Gangliosides are part of the larger family
of glycosphingolipids and are components of the synaptic
plasma membrane involved in synaptic plasticity, signal
transduction, and endocytosis and then are critical for
CNS development. B4GALNT1 catalyzes the transfer of
N-acetyl-galactosamine into GM3, GD3, and globotriaosyl-
ceramideby ab-1,4 linkage (Figure 3). The reverse reaction is
performed by b-hexosaminidase and its cofactor (GM2 acti-
vator). Molecular defects in the degradation of glycosphin-
golipids led to well-known lysosomal storage diseases,
including Gaucher disease caused by GBA (MIM 606463)
mutations,16,17 Fabry disease (MIM 301500), metachro-
matic leukodystrophy (MIM 250100 and 249900), Tay-
Sachs AB variant/GM2 gangliosidosis (MIM 272750),
Sandhoff disease (MIM 268800), and GM1 gangliosidosis
(MIM 230500) (Figure 3). Conversely, to our knowledge, a
single proven case of a human disorder resulting from
disruption of ganglioside biosynthesis has been
described.18 Mutations in ST3GAL5 (also known as SIAT9
[MIM 604402]) coding for GM3 synthase, also called lacto-
sylceramide a-2,3 sialyltransferase, resulted in infantile
epileptic encephalopathy (MIM 609056) with severe devel-
opmental delay and blindness. ST3GAL5-mutated individ-
uals displayed a complete lack of plasmaGM3and its down-
stream biosynthetic derivatives but had increased levels of
plasma lactosylceramideand increasedflux throughtheglo-The Amboside and paragloboside pathways.18 Therefore, SPG26 re-
sulting from B4GALNT1 mutations is the second ganglio-
side biosynthesis defect and is expected to lead to the
accumulation of globotriaosylceramide and gangliosides G
[M/D/T]3. Of note, another complex AR HSP, SPG46 (MIM
614409), is caused by loss-of-function mutations in GBA2
(MIM609471), coding for an enzyme acting on glucosylcer-
amides, substrates of lactosylceramides (Figure 3).8
The clinical features of 18 affected individuals from the
7 SPG26 families identified in this study are summarized
in Table S2. Gait difficulties occurred early, from 2 to 19
years of age. All subjects had predominant spasticity of
the lower limbs (with variable spastic involvement of
the upper limbs in 33%), increased reflexes, and bilateral
Babinski sign. Pseudobulbar dysarthria was present in
47% (7/15). After a mean disease duration of 32.2 5
19.5 years (range 1–60), four subjects were confined to a
wheelchair or bedridden. Severity was variable: one was
bedridden after 13 years (TUN34-11) whereas another
was confined to a wheelchair after 47 years of disease evo-
lution (FSP995-17). Lower motor neuron involvement was
variably present, indicated by lower limb muscle wasting
(11/18, 61%) at later disease stages, decrease or absence
of lower limb tendon reflexes (11/18, 61%) during the
course of the disease (as in family THI26004), and periph-
eral neuropathy predominantly of the axonal type in
four families (7/11, 64%). Mild to moderate cognitive
impairment and developmental delay was noted in all in-
dividuals, often preceding motor deficits. Cognitive
dysfunction was noted to worsen with time in some sub-
jects. Cerebellar signs (10/18, 55%) and extrapyramidal
signs (8/18, 44%), such as facial dyskinesia and dystonia,
were also noted. Further commonly observed signs and
symptoms included bladder disturbances (6/18, 33%),
peripherally decreased vibration sense (9/15, 60%), scoli-
osis (10/15, 67%), pes cavus (9/16, 56%), and strabismus
(4/18, 22%). Four subjects had psychiatric features (the
three German cases and one Brazilian individual). Inerican Journal of Human Genetics 93, 118–123, July 11, 2013 121
addition, several signs were confined to one family: mild
dysmorphic features in the Brazilian subjects and congen-
ital posterior capsular cataract in the three Spanish indi-
viduals. Brain magnetic resonance imaging (MRI) was
either normal or, after long disease durations, showed
cortical atrophy (n ¼ 5/10), subcortical atrophy (n ¼ 1/
10), and/or white matter hyperintensities (WMHs) on
FLAIR sequence (n ¼ 4/10) (Figure S2). In subject
FSP995-19, WMHs worsen with time, as observed in two
brain MRIs performed 12 years apart. We noted a slightly
enlarged corpus callosum in 4/10 subjects; some of them
with otherwise unremarkable MRIs. Finally, serum testos-
terone was reduced or at the lower limit in four of the six
young men tested (67%), and one of them (IHG25297-
105) had hypogonadism and delayed puberty.
Interestingly, the B4galnt1/ mouse19 shows progres-
sive gait disorder reminiscent of clinical features of
SPG26. This phenotype could result from decreased central
myelination in dorsal spinal cord and increased numbers
of unmyelinated fibers,20,21 increased astrocyte/microglia
proliferation, or alteration of lipid content in glycolipid-
enrichedmembrane (raft) domains.22,23 Cerebellar granule
cells of B4galnt1/ mice are also more prone to degenera-
tion in depolarizing conditions, very probably due to an
alteration of calcium homeostasis.24 In addition, knockout
males have progressive testicular atrophy with the pres-
ence of diffuse vacuoles in Sertoli cells and, despite almost
normal testosterone levels per mg of testis, a severe reduc-
tion of serum testosterone.25 All these phenotypes could
be due to the accumulation of globotriaosylceramide and
simple gangliosides and/or the lack of complex ganglio-
sides.19,24 Interestingly, GM3 accumulation has been re-
ported in a simplex case with liver and brain disease.26,27
Whether the disease in this subject is the result of a muta-
tion in B4GALNT1 remains unknown.
In conclusion, we used a combined mapping and exome
sequencing approach to identify B4GALNT1 variants as the
cause of an AR complicated form of HSP. This was achieved
with18SPG26-affected individuals that belonged to7unre-
lated families from Europe, South America, and North
Africa (indicating theworld-wide distribution of this partic-
ular formofHSP). In accordancewith previous reports,9 the
phenotype of SPG26 consisted in early-onset and slowly
progressive spastic paraparesis and cognitive impairment,
complicated by cerebellar ataxia. We extended this clinical
spectrum to include extrapyramidal involvement and pe-
ripheral neuropathy as well as cortical atrophy with white
matter hyperintensities at brain MRI and low levels of
testosterone in males. Disease progression seemed slow:
most affected subjects were still able to walk after long dis-
ease durations but heterogeneity in disease progression
was frequent among families. Altogether, SPG26 is the sec-
ondhumandisorder of ganglioside biosynthesis. Abnormal
glycosphingolipid profile may be detectable in peripheral
samples from SPG26 subjects: this would hasten clinical
diagnosis and facilitate monitoring in therapeutic trials as
for other HSPs, such as SPG5A (MIM 270800) associated122 The American Journal of Human Genetics 93, 118–123, July 11, 2with 25- and 27-hydroxycholesterol accumulation28 and
X-linked adrenoleukodystrophy (MIM 300100).
Supplemental Data
Supplemental Data include two figures and two tables and can be
found with this article online at http://www.cell.com/AJHG/.
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